Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
Carlos Doti, VP US Medical Affairs Oncology at AstraZeneca, shared on LinkedIn:
”As I reflect on another ASH, I’m reminded why this meeting is such a powerful close to the year – where science, collaboration and patient experiences come together to shape the future of hematology.
This year, I participated in two meaningful AstraZeneca events:
Moderating our annual Patient Advocacy Exchange panel with advocacy leaders focused on shared decision-making and patient navigation, discussing how to break down barriers and promote equitable access to care.
Hosting our first-ever AZHemeTalks – a live, pop-up series – at our booth, where I spoke with a clinical trial patient and her doctor about how treatment choices impact daily life.
The video here shows how we brought this activation to life through 4 expert panels focused on the treatment landscape in leukemia, lymphomas and multiple myeloma.”
Stay updated with Hemostasis Today.
-
Jul 2, 2026, 19:40Minoo Ahmadinejad: Improving the Recognition of Women and Girls With Hemophilia
-
Jul 2, 2026, 19:26Dhinesh Selvaraju: FDA Expands Access to HYMPAVZI in Hemophilia
-
Jul 2, 2026, 19:13Syed Fahad Hussain: Not Every Low Platelet Count Tells the Same Story
-
Jul 2, 2026, 18:59Indu Thakur: Supporting Blood Donation Through Public Awareness in MSBT
-
Jul 2, 2026, 18:47Vee Townsend: IMHUE Highlights 9 Myths and Facts About Hemophilia B
-
Jul 2, 2026, 17:17Nico Gagelmann: Launching Myths and Facts on Hematology and Cell Therapy
-
Jul 2, 2026, 17:05Haroun Gajraj: Understanding the Technology Behind Spider Vein Treatment
-
Jul 2, 2026, 16:44Ney Carter Borges: Is It Time to Personalize Antiplatelet Therapy?
-
Jul 2, 2026, 16:22Introducing a New Resource for the ITP Community – ITP Support Association